Beyond Air Inc SEC Filings

Beyond Air, Inc. (XAIR) filed a Form 4 reporting that its Chief Operating Officer had existing stock options repriced. On November 4, 2025, the Board of Directors approved an option repricing, effective the same day, reducing the exercise price of several option grants to $1.95 per share, which was the closing price of Beyond Air’s common stock on November 3, 2025. All other terms of the options, including the number of shares and expiration details, remain unchanged.

The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan. They become exercisable based on the vesting schedule in the original award agreements, which continue to require the reporting person’s ongoing service with the company on each vesting date.

Beyond Air, Inc. has filed a Form S-1 to register the resale of up to 1,600,000 shares of common stock that may be issued to Streeterville Capital, LLC under an Equity Purchase Agreement. These shares, called Put Shares, will be issued over time at prices tied to the market price of XAIR stock, and Streeterville will act as an underwriter in reselling them.

The company may sell common stock to Streeterville for cash or, after certain offset events, by cancelling amounts outstanding under a $12,050,000 secured promissory note. Beyond Air may receive up to $20,000,000 in gross proceeds from sales of shares to Streeterville, but it will receive no proceeds from Streeterville’s resale of the registered shares. As of November 20, 2025, Beyond Air had 8,009,488 shares of common stock outstanding. The equity line is subject to a 4.99% beneficial ownership cap and Nasdaq’s 19.99% share issuance limitation.

Beyond Air (XAIR) reported Q2 FY2026 results. Revenue was $1.8 million, up from $0.8 million a year ago, but cost of revenues of $2.1 million produced a gross loss of $0.3 million. Operating expenses were $7.4 million, leading to a loss from operations of $7.7 million and a net loss of $8.3 million (basic and diluted loss per share $1.25).

Cash, cash equivalents, marketable securities and restricted cash totaled $10.9 million as of September 30, 2025. The company raised $8.1 million via its ATM program and received $2.9 million from warrant exercises during the six months. Long‑term debt, net, was $10.1 million, and management disclosed that recent results and projected cash outflows raise “substantial doubt” about the ability to meet obligations without additional financing.

The LungFit PH leasing business recognized $1.4 million in revenue in the quarter, and minimum future lease payments contracted total $11.1 million through 2029. Shares outstanding were 8,009,488 as of November 7, 2025; this is a baseline figure, not the amount being offered.

Beyond Air (XAIR) reported an insider equity update: a director’s outstanding stock options were repriced by the board to an exercise price of $1.95 per share, effective November 4, 2025. The new price matches the closing price on November 3, 2025, and all other terms, including vesting, remain unchanged under the company’s Amended and Restated 2013 Equity Incentive Plan.

The filing lists multiple option grants adjusted from prior exercise prices of $10.80 and $5.892 to $1.95, with representative tranches of 10,000, 4,500, 2,000, 1,500, and 1,250 options now reflecting the revised strike price.

Beyond Air, Inc. (XAIR) director reported warrant transactions on Form 4. In connection with a $2,000,000 loan to the company, the reporting person acquired warrants to purchase up to 512,821 shares at $1.95. Separately, an outstanding warrant for 494,332 shares at $7.586 was cancelled and a replacement warrant for 494,332 shares at $1.95 was issued. The warrants are exercisable on or after issuance and expire five years from their respective issuance dates.

Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing. On November 4, 2025, the board reduced the exercise price of certain outstanding stock options to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025.

The Form 4 shows multiple option awards previously carrying exercise prices of $10.80 and $5.892, each adjusted to $1.95. The company states that all other terms of the options remain unchanged. These options were granted under the Amended and Restated 2013 Equity Incentive Plan and continue to follow their existing vesting schedules, subject to the director’s continued service.

Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.

The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.

Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.

The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.

Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.

The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.